Daphna Yael Spiegel, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Rectal Neoplasms | 3 | 2020 | 1195 | 1.080 |
Why?
|
| Veterans Health | 2 | 2019 | 216 | 0.750 |
Why?
|
| Radiation Oncology | 3 | 2023 | 554 | 0.680 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2020 | 874 | 0.640 |
Why?
|
| Lymph Node Excision | 2 | 2023 | 1248 | 0.620 |
Why?
|
| Nomograms | 1 | 2018 | 224 | 0.580 |
Why?
|
| Carcinoma, Intraductal, Noninfiltrating | 2 | 2023 | 947 | 0.490 |
Why?
|
| Brachytherapy | 2 | 2018 | 1246 | 0.470 |
Why?
|
| Neoadjuvant Therapy | 3 | 2020 | 2721 | 0.420 |
Why?
|
| Androgen Antagonists | 1 | 2018 | 1350 | 0.360 |
Why?
|
| Calcinosis | 1 | 2017 | 1497 | 0.320 |
Why?
|
| Patient Protection and Affordable Care Act | 1 | 2018 | 1208 | 0.320 |
Why?
|
| Testosterone | 1 | 2018 | 2401 | 0.310 |
Why?
|
| Stomach Neoplasms | 1 | 2017 | 1327 | 0.300 |
Why?
|
| Insurance Coverage | 1 | 2018 | 1895 | 0.290 |
Why?
|
| Adenocarcinoma | 3 | 2018 | 6347 | 0.240 |
Why?
|
| Rectum | 2 | 2020 | 903 | 0.240 |
Why?
|
| Axilla | 2 | 2023 | 588 | 0.240 |
Why?
|
| Prostatic Neoplasms | 5 | 2018 | 11039 | 0.240 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2020 | 11472 | 0.210 |
Why?
|
| Breast Neoplasms | 5 | 2023 | 20774 | 0.200 |
Why?
|
| Chemotherapy, Adjuvant | 3 | 2020 | 3471 | 0.190 |
Why?
|
| Disease-Free Survival | 3 | 2020 | 6891 | 0.170 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2020 | 6534 | 0.170 |
Why?
|
| Neoplasms | 2 | 2018 | 21596 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 9185 | 0.170 |
Why?
|
| Fiber Optic Technology | 1 | 2020 | 289 | 0.160 |
Why?
|
| Radiosurgery | 2 | 2018 | 1309 | 0.140 |
Why?
|
| Mammography | 2 | 2018 | 2474 | 0.140 |
Why?
|
| Lymphedema | 1 | 2023 | 528 | 0.140 |
Why?
|
| Hospitals, Veterans | 1 | 2019 | 404 | 0.140 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2018 | 627 | 0.130 |
Why?
|
| Laryngoscopy | 1 | 2020 | 706 | 0.120 |
Why?
|
| Small Cell Lung Carcinoma | 1 | 2019 | 384 | 0.120 |
Why?
|
| Breast | 2 | 2023 | 1958 | 0.110 |
Why?
|
| Neoplasm Staging | 5 | 2020 | 11001 | 0.110 |
Why?
|
| Genital Neoplasms, Female | 1 | 2018 | 516 | 0.110 |
Why?
|
| Medically Uninsured | 1 | 2018 | 852 | 0.110 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2017 | 1769 | 0.100 |
Why?
|
| Lymph Nodes | 1 | 2023 | 3465 | 0.100 |
Why?
|
| Radiotherapy, Conformal | 2 | 2014 | 548 | 0.090 |
Why?
|
| Middle Aged | 11 | 2020 | 213127 | 0.090 |
Why?
|
| Aged | 10 | 2020 | 162944 | 0.090 |
Why?
|
| Carcinoma, Ductal | 1 | 2010 | 101 | 0.090 |
Why?
|
| Humans | 19 | 2023 | 742088 | 0.090 |
Why?
|
| United States | 5 | 2023 | 69693 | 0.090 |
Why?
|
| Uterine Neoplasms | 1 | 2018 | 1513 | 0.080 |
Why?
|
| Urologic Surgical Procedures | 1 | 2011 | 301 | 0.080 |
Why?
|
| Mastectomy | 1 | 2017 | 1789 | 0.080 |
Why?
|
| Proportional Hazards Models | 3 | 2019 | 12344 | 0.080 |
Why?
|
| Survivors | 1 | 2018 | 2286 | 0.080 |
Why?
|
| Hospitals, General | 1 | 2011 | 749 | 0.070 |
Why?
|
| Multivariate Analysis | 2 | 2018 | 12242 | 0.070 |
Why?
|
| Combined Modality Therapy | 1 | 2018 | 8621 | 0.070 |
Why?
|
| Cystectomy | 1 | 2011 | 682 | 0.070 |
Why?
|
| Neoplasm Metastasis | 1 | 2017 | 4839 | 0.070 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2018 | 2011 | 0.070 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 2712 | 0.070 |
Why?
|
| Pituitary Neoplasms | 1 | 2014 | 1340 | 0.070 |
Why?
|
| Patient Care Team | 1 | 2017 | 2527 | 0.070 |
Why?
|
| Medicaid | 1 | 2018 | 2716 | 0.060 |
Why?
|
| Female | 11 | 2023 | 379592 | 0.060 |
Why?
|
| Clinical Trials as Topic | 2 | 2018 | 7901 | 0.060 |
Why?
|
| Male | 10 | 2020 | 349538 | 0.060 |
Why?
|
| Adenoma | 1 | 2014 | 2168 | 0.060 |
Why?
|
| Aged, 80 and over | 6 | 2019 | 57683 | 0.060 |
Why?
|
| Registries | 1 | 2018 | 8077 | 0.050 |
Why?
|
| Positron-Emission Tomography | 1 | 2019 | 6259 | 0.050 |
Why?
|
| Internship and Residency | 1 | 2020 | 5774 | 0.040 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2011 | 2229 | 0.040 |
Why?
|
| Sentinel Lymph Node Biopsy | 1 | 2023 | 701 | 0.040 |
Why?
|
| Prospective Studies | 1 | 2023 | 53187 | 0.040 |
Why?
|
| Treatment Outcome | 4 | 2018 | 62966 | 0.040 |
Why?
|
| Quality of Life | 1 | 2018 | 12730 | 0.040 |
Why?
|
| Adult | 4 | 2018 | 213712 | 0.040 |
Why?
|
| Radiotherapy Dosage | 2 | 2014 | 2876 | 0.030 |
Why?
|
| Reactive Oxygen Species | 1 | 2023 | 2077 | 0.030 |
Why?
|
| Young Adult | 2 | 2018 | 56350 | 0.030 |
Why?
|
| Lung Neoplasms | 1 | 2019 | 13019 | 0.030 |
Why?
|
| Necrosis | 1 | 2018 | 1643 | 0.030 |
Why?
|
| Hypopituitarism | 1 | 2014 | 254 | 0.030 |
Why?
|
| Acromegaly | 1 | 2014 | 347 | 0.030 |
Why?
|
| Thyrotropin | 1 | 2014 | 850 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2020 | 5062 | 0.020 |
Why?
|
| Students, Medical | 1 | 2020 | 1858 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2019 | 9846 | 0.020 |
Why?
|
| Health Expenditures | 1 | 2018 | 2346 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 39004 | 0.020 |
Why?
|
| Comorbidity | 1 | 2019 | 10372 | 0.020 |
Why?
|
| Neoplasm Invasiveness | 1 | 2011 | 3612 | 0.010 |
Why?
|
| Pandemics | 1 | 2023 | 8328 | 0.010 |
Why?
|
| Medicare | 1 | 2018 | 6532 | 0.010 |
Why?
|
| Boston | 1 | 2011 | 9305 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2018 | 77098 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2011 | 23320 | 0.010 |
Why?
|
| Time Factors | 1 | 2011 | 40054 | 0.010 |
Why?
|
| Child | 1 | 2014 | 77478 | 0.000 |
Why?
|
| Adolescent | 1 | 2014 | 85649 | 0.000 |
Why?
|
| Risk Factors | 1 | 2011 | 72145 | 0.000 |
Why?
|